{"title":"Risk of allergic rhinitis in patients with inflammatory bowel disease: A systematic review and meta-analysis.","authors":"Jie Liu, Lun Cai, Rongrong Yang, Liping Wei, Huazheng Luo, Xiongbin Gui","doi":"10.15586/aei.v51i6.943","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Numerous parallels exist between inflammatory bowel disease (IBD) and allergic rhinitis (AR), which include risk factors (such as environmental and genetic factors), pathogenesis (immune disorders, epithelial cell barriers, etc.), and treatment (immunosuppressants and immunomodulators, such as cyclosporine and steroids). However, the risk of AR in IBD patients is unknown.</p><p><strong>Objective: </strong>In this systematic review and meta-analysis, patients with IBD are examined for their risk of AR.</p><p><strong>Methods: </strong>Several databases are accessible in both Chinese and English, including PubMed, BioRXiv, WanFang, the China National Knowledge Infrastructure (CNKI), Web of Science, METSTR, and MedRxiv. Findings presented at allergy, rhinology, thoracic, and gastrointestinal conferences were analyzed. Based on the inclusion and exclusion criteria, two evaluators independently retrieved data, read the literature, and evaluated bias risk. The data analysis was conducted using RevMan 5.4. Case-control and cohort studies were eligible study designs for this research.</p><p><strong>Results: </strong>There were 10 case-control studies and 1 cohort study included in the meta-analysis. The experimental group consisted of 65,687 IBD patients, of whom 5838 had AR. A total of 345,176 participants without IBD were included in the control group, of whom 24,625 developed AR. The outcomes demonstrated that IBD patients had a higher risk of developing AR (odds ratio [OR] = 1.48, 95% confidence interval [CI] [1.12, 1.95], Z = 2.78, P = 0.005) than those without IBD.</p><p><strong>Conclusion: </strong>The risk of AR is higher in IBD patients. Further investigation is required to determine the mechanism behind the association between AR and IBD.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergologia et immunopathologia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.15586/aei.v51i6.943","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Numerous parallels exist between inflammatory bowel disease (IBD) and allergic rhinitis (AR), which include risk factors (such as environmental and genetic factors), pathogenesis (immune disorders, epithelial cell barriers, etc.), and treatment (immunosuppressants and immunomodulators, such as cyclosporine and steroids). However, the risk of AR in IBD patients is unknown.
Objective: In this systematic review and meta-analysis, patients with IBD are examined for their risk of AR.
Methods: Several databases are accessible in both Chinese and English, including PubMed, BioRXiv, WanFang, the China National Knowledge Infrastructure (CNKI), Web of Science, METSTR, and MedRxiv. Findings presented at allergy, rhinology, thoracic, and gastrointestinal conferences were analyzed. Based on the inclusion and exclusion criteria, two evaluators independently retrieved data, read the literature, and evaluated bias risk. The data analysis was conducted using RevMan 5.4. Case-control and cohort studies were eligible study designs for this research.
Results: There were 10 case-control studies and 1 cohort study included in the meta-analysis. The experimental group consisted of 65,687 IBD patients, of whom 5838 had AR. A total of 345,176 participants without IBD were included in the control group, of whom 24,625 developed AR. The outcomes demonstrated that IBD patients had a higher risk of developing AR (odds ratio [OR] = 1.48, 95% confidence interval [CI] [1.12, 1.95], Z = 2.78, P = 0.005) than those without IBD.
Conclusion: The risk of AR is higher in IBD patients. Further investigation is required to determine the mechanism behind the association between AR and IBD.
背景：炎症性肠病（IBD）和过敏性鼻炎（AR）之间存在许多相似之处，包括风险因素（如环境和遗传因素）、发病机制（免疫障碍、上皮细胞屏障等）和治疗（免疫抑制剂和免疫调节剂，如环孢菌素和类固醇）。然而，IBD患者发生AR的风险尚不清楚。目的：在这项系统综述和荟萃分析中，对IBD患者的AR风险进行了检查。方法：可以访问几个中英文数据库，包括PubMed、BioRXiv、WanFang、中国知识基础设施（CNKI）、Web of Science、METSTR和MedRxiv。对过敏、鼻科、胸部和胃肠道会议上的研究结果进行了分析。根据纳入和排除标准，两名评估者独立检索数据，阅读文献，并评估偏倚风险。使用RevMan 5.4进行数据分析。病例对照和队列研究是本研究的合格研究设计。结果：荟萃分析包括10项病例对照研究和1项队列研究。实验组由65687名IBD患者组成，其中5838人患有AR。对照组共有345176名无IBD的参与者，其中24625人患上了AR。结果表明，IBD患者发生AR的风险高于无IBD患者（比值比[OR]=1.48，95%可信区间[CI][1.12，1.95]，Z=2.78，P=0.005）。需要进一步的调查来确定AR和IBD之间的联系背后的机制。
期刊介绍：
Founded in 1972 by Professor A. Oehling, Allergologia et Immunopathologia is a forum for those working in the field of pediatric asthma, allergy and immunology. Manuscripts related to clinical, epidemiological and experimental allergy and immunopathology related to childhood will be considered for publication. Allergologia et Immunopathologia is the official journal of the Spanish Society of Pediatric Allergy and Clinical Immunology (SEICAP) and also of the Latin American Society of Immunodeficiencies (LASID). It has and independent international Editorial Committee which submits received papers for peer-reviewing by international experts. The journal accepts original and review articles from all over the world, together with consensus statements from the aforementioned societies. Occasionally, the opinion of an expert on a burning topic is published in the "Point of View" section. Letters to the Editor on previously published papers are welcomed. Allergologia et Immunopathologia publishes 6 issues per year and is included in the major databases such as Pubmed, Scopus, Web of Knowledge, etc.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
